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Abstract
Background: There is an inverse relationship between febrile infection and the risk of malignancies. Interferon gamma (IFN-
c) plays an important role in fever induction and its expression increases with incubation at fever-range temperatures.
Therefore, the genetic polymorphism of IFN-c may modify the association of febrile infection with breast cancer risk.
Methodology and Principal Findings: Information on potential breast cancer risk factors, history of fever during the last 10
years, and blood specimens were collected from 839 incident breast cancer cases and 863 age-matched controls between
October 2008 and June 2010 in Guangzhou, China. IFN-c (rs2069705) was genotyped using a matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry platform. Odds ratios (OR) and 95% confidence intervals (CIs) were
calculated using multivariate logistic regression. We found that women who had experienced $1 fever per year had a
decreased risk of breast cancer [ORs and 95% CI: 0.77 (0.61–0.99)] compared to those with less than one fever a year. This
association only occurred in women with CT/TT genotypes [0.54 (0.37–0.77)] but not in those with the CC genotype [1.09
(0.77–1.55)]. The association of IFN-c rs2069705 with the risk of breast cancer was not significant among all participants,
while the CT/TT genotypes were significantly related to an elevated risk of breast cancer [1.32 (1.03–1.70)] among the
women with ,1 fever per year and to a reduced risk of breast cancer [0.63 (0.40–0.99)] among women with $1 fever per
year compared to the CC genotype. A marked interaction between fever frequencies and the IFN-c genotypes was observed
(P for multiplicative and additive interactions were 0.005 and 0.058, respectively).
Conclusions: Our findings indicate a possible link between febrile acute infection and a decreased risk of breast cancer, and
this association was modified by IFN-c rs2069705.
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Introduction
Since the 19
th century, it has been repeatedly observed that
spontaneous cancer regressions were coincided with acute
infections and the cancer patients had a remarkable disease-free
history before the onset of cancer [1–4]. In the 20
th century, an
inverse association between infectious diseases, particularly febrile
ones, and cancer risk has also been consistently found for
malignant melanoma and glioma using modern epidemiological
methods [1,3,5–7].
With the widespread introduction of antibiotics and antipyretics
since the beginning of the last century, however, the critical role
played by fever has often been overlooked, resulting in consider-
able changes to the clinical course and magnitude of the immune
response that develops following acute infections [1,8]. These
changes may be part of the reasons for the substantial increase in
the age-adjusted incidences or mortalities of malignant diseases
during the early part of the last century in western countries [9]
and in the late of the last century in China [10]. It has been
observed that every 2% reduction in infectious disease mortality
was followed by a 2% increase in cancer mortality over a 10-year
interval from 1895 to 1963 in Italy [9]. Conventional cancer
treatments have made slow progress and cancer is still an incurable
ailment. Under these circumstances, there are important implica-
tions for the re-exploration of this hidden treasure buried in
time—that fever induced by acute infection may be antagonistic to
cancer development [2,4]. We may take the advantage of fever,
the beneficial aspect of acute infections, to prevent and treat
cancer because we are able to induce and control fever much
better than before [4].
Increased body temperature has been shown to stimulate the
immune system through the augmentation of T and NK cell
activity and the production of cytokines, including interferon
gamma (IFN-c) [11–13]. The IFN-c expression has been found to
increase along with the artificial elevation of fever-range temper-
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increase after feverish infection [13]. In turn, IFN-c is able to
induce fever and can be considered an independent endogenous
pyrogen in humans and rabbits [19–22]. Fever has been shown to
be a constant side effect encountered with IFN-c treatments
[23,24]. Moreover, a high level of IFN-c expression shows
antitumor activity [25] and IFN-c inhibits the growth of many
cell lines that originate from tumors, including breast cancer [26].
In addition, a potentially functional single nucleotide polymor-
phism (SNP, rs2069705) in IFN-c (21615 C/T) [27,28] has been
reported to be associated with breast cancer risk [29]. Therefore,
there may be interplay between febrile infection and IFN-c in
relation to breast cancer risk.
In the present study, we evaluated the association of febrile
acute infection with breast cancer risk, and further investigated
whether this association is modified by IFN-c polymorphism
(rs2069705) in a case-control study in Guangzhou, China.
Results
Fever frequencies and genotypes in cases and controls
Breast cancer cases, compared to similarly aged controls, were
more likely to be premenopausal and low educated. They were
comparable in terms of marital status, body mass index (BMI), age
at menarche, parity, and family history of breast cancer (Table 1).
The proportions for different fever frequencies of below once, 1,2
times, 3,4 times, and 5 times or above per year were 76.1%,
19.3%, 3.3%, and 1.4% for patients and 72.1%, 23.0%, 3.3% and
1.5% for controls, respectively.
After adjustment for potential breast cancer risk factors, women
who had experienced 1,2 fevers per year and 3 fevers or more
per year exhibited a significant and a non-significant decreased
risk of breast cancer compared to those who experienced below
one fever a year with ORs and 95% CIs of 0.77 (0.59–1.00) and
0.79 (0.47–1.32), respectively (Table 2). The non-significant
decrease in breast cancer risk was probably the result of the small
sample size at this level (only 34 cases and 38 controls). Given that
the direction of the two ORs is the same, we combined these two
levels. The ORs and 95% CIs for the combined level of fever
frequency ($1 times per year) were 0.77 (0.61–0.99) in the
multivariate model (Table 2). The genotypes of IFN-c rs2069705
were equally distributed in cases and controls and, consequently,
were not significantly associated with breast cancer risk (Table 2).
Associations of fever frequency and IFN-c genotypes with
breast cancer risk in subgroups of clinicopathological
features
Subsequently, we attempted to examine whether the disease
process per se or clinical characteristics affect the association of the
genotypes and fever frequencies with breast cancer risk by carrying
out several exploratory stratified analyses. Similar associations
between breast cancer risk and fever frequency were observed
across menopausal, clinical stage, and HER2 statuses (Table 3).
Although the reduced risk was slightly more evident among
women with BMI$24 (OR=0.53, 95% CI=0.33–0.84) and
patients with ER negative (OR=0.67, 95% CI=0.45–1.00) or
with PR negative (OR=0.66, 95% CI=0.46–0.94), the P values
for interaction or heterogeneity were not significant (Table 3).
Meanwhile, the IFN-c genotypes were not significantly associated
with the risk of breast cancer in each stratum and no interaction
between them on breast cancer risk occurred (Table 3).
Joint effects of fever frequency and IFN-c genotypes on
breast cancer risk
Finally, the joint effects of fever frequency and IFN-c genotypes
on breast cancer risk were analyzed. Compared to women who
Table 1. Characteristics of breast cancer cases and controls.
Characteristic
Cases,
n (%)
Controls,
n (%) P value
Age
#40 210 (25.0) 226 (26.2)
41,59 494 (58.9) 491 (56.9)
60, 135 (16.1) 146 (16.9) 0.709
Mean 6 SD 48.97611.57 49.23611.76 0.654
b
Education
Junior middle school or below 389 (46.4) 315 (36.5)
Senior middle school 216 (25.7) 326 (37.8)
College or above 174 (20.7) 188 (21.8) ,0.001
Unknown 60 (7.2) 34 (3.9)
Marital status
Never married 41 (4.9) 33 (3.8)
Married/living as married 711 (84.7) 717 (83.1)
Separated/widow 46 (5.5) 63 (7.3) 0.182
Unknown 41 (4.9) 50 (5.8)
Body mass index (kg/m
2)
,22 349 (41.6) 338 (39.2)
22,24 240 (28.6) 273 (31.6)
$25 206 (24.6) 196 (22.7) 0.293
Unknown 44 (5.2) 56 (6.5)
Age at menarche (years)
#12 109 (13.0) (15.5)
.12 682 (81.3) 689 (79.8) 0.160
Unknown 48 (5.7) 40 (4.6)
Menopausal status
Premenopausal 479 (57.1) 402 (46.6)
Postmenopausal 338 (40.3) 430 (49.8) ,0.001
Unknown 22 (2.6) 31 (3.6)
Age at menopause (years)
a
#45 72 (21.3) 72 (16.7)
46,50 (38.5) 182 (42.3)
.50 99 (29.3) 155 (36.1) 0.096
Unknown 37 (11.0) 21 (4.9)
Parity
0 73 (8.7) 59 (6.8)
$1 732 (87.3) 772 (89.5)
Unknown 34 (4.1) 32 (3.7) 0.144
Family history of breast cancer
Absent 780 (93.0) 800 (92.7)
Present 25 (3.0) 28 (3.2) 0.753
Unknown 34 (4.1) 35 (4.1)
aPostmenopausal women only.
bStudent’s t-test.
P values in bold indicate statistical significance.
doi:10.1371/journal.pone.0037275.t001
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fever or above per year was more evident among women with the
CT/TT genotypes than among those with the CC genotype with
ORs and 95% CIs of 0.54 (0.37–0.77) and 1.09 (0.77–1.55),
respectively (Table 4). Compared to women with the CC
genotype, the risk of breast cancer in women with the CT/TT
genotypes was significantly elevated among women with ,1 fever
per year, whereas it was significantly reduced among women with
$1 fever per year. The ORs and 95% CIs were 1.32 (1.03–1.70)
and 0.63 (0.40–0.99), respectively (Table 4). A marked interaction
between fever frequencies and the IFN-c genotypes on breast
cancer risk was observed (P for multiplicative and additive
interaction were 0.005 and 0.058, respectively).
Discussion
Acute infections are often accompanied by inflammatory
reactions including fever, which is a cytokine-mediated rise in
core temperature, and other immunologic, endocrinologic, neu-
rologic, and physiologic changes [1,30]. A fever can establish a
cascade of host defense mechanisms by inducing the proliferation
and differentiation of leucocytes and the secretion of interferons
(IFNs), tumor necrosis factor (TNF)-a, antibodies, and neutrophil
migration [11,12]. It has also been shown both in vitro and in vivo
that dendritic cells (DC, key antigen-presenting cells in the
immune system) treated with fever-like heat (41uC) were signifi-
cantly superior compared to non-heat-treated DC in stimulating T
cells and activating NF-kB (a transcription factor that regulates
various immunological genes and plays an important role in
human tumor suppression) [5,15]. Moreover, tumor cells are more
vulnerable to heat than normal cells and undergo necrosis to a
larger extent [31,32] and hyperthermia has become an auxiliary
approach in cancer therapy [14,33–36]. In addition, several
epidemiological studies have consistently found an inverse
association between febrile acute infections and cancer risk
[1,3,5–7,37–39], especially for malignant melanoma, which have
been shown a link to breast cancer in epidemiologic and genetic
studies [40–42]. Therefore, our finding of an inverse association
between fever frequency and breast cancer risk is in agreement
with the results of previous studies.
IFN-c is one of the main products of Th1-specific proin-
flammatory cytokines and has an effect on host defense and
immune regulation, such as antivirus, antimicrobe, and antitumor
activities [43]. It has also been shown to have a high correlation to
tumor regression in immunotherapy, but these results were mixed
as to the efficacy in clinical trials [43]. Several studies have
examined the association of polymorphisms in the IFN-c gene,
mainly rs2069705 (21615 C/T) and rs2430561 (+874 T/A), with
the risk of breast cancer [29,44–47], but these results also
conflicted with null, positive, and inverse associations. In the
present study, we found a null association of IFN-c rs2069705 with
the risk of breast cancer among the study participants as a whole.
However, we observed a positive association among the women
with ,1 fever per year but an inverse association among women
with $1 fever per year for the CT/TT genotypes and breast
cancer risk. These phenomena may explain the previously
mentioned inconsistent results to some extent, and suggest that
IFN-c plays a role in tumorigenesis depending on certain
environments, such as febrile infections.
The evidence of interplay between fevers and IFN-c has been
noted in previous experimental studies that show how fever can
induce IFN-c and be induced by IFN-c [14–16,19–22]. Moreover,
it has been shown that a low level of IFN-c promotes tumor
development and a high level of IFN-c mediates significant
antitumor effects [25]. Based on the evidence that the T allele is
associated with a higher level of IFN-c than the C allele
[27,28,48], the co-existence of a fever and the T allele of IFN-c
rs2069705 might increase the IFN-c level high enough to make the
host’s anticancer defense more effective while the co-existence of
less fever and the T allele might keep IFN-c at a certain low level
to promote tumourgenesis, supporting our results to some extent
that women with CT/TT genotypes and $1 fever per year have a
decreased breast cancer risk and women with CT/TT genotypes
and ,1 fever per year have an increased breast cancer risk.
Nevertheless, the exact mechanisms in which fever and IFN-c
interact on breast cancer risk remain to be studied.
Several potential limitations of this study should be mentioned.
In a case-control study, it is unrealistic to blind disease status for
interviewers and the study is subject to unconscious interviewer
bias. We have attempted to reduce this potential bias source as
Table 2. Multivariate odds ratio of breast cancer risk associated with previous fever frequency and IFN-c genotypes.
Variables Cases, n (%) Controls, n (%) OR (95%CI)
a OR (95%CI)
b
Fever frequency (/year)
,1 time 556 (76.1) 560 (72.1) 1.00 (reference) 1.00 (reference)
1,2 times 141 (19.3) 179 (23.0) 0.79 (0.62–1.02) 0.77 (0.59–1.00)
$3 times 34 (4.7) 38 (4.9) 0.90 (0.56–1.45) 0.79 (0.47–1.32)
P for trend 0.136 0.056
$1 time 175 (23.9) 217 (27.9) 0.81 (0.64–1.02) 0.77 (0.61–0.99)
IFN-c rs2069705
CC 407 (50.4) 442 (52.6) 1.00 (reference) 1.00 (reference)
CT 332 (41.1) 342 (40.7) 1.05 (0.86–1.29) 1.06 (0.86–1.31)
TT 68 (8.4) 56 (6.7) 1.32 (0.90–1.93) 1.28 (0.87–1.90)
P for trend 0.204 0.245
CT+TT 400 (49.6) 398 (47.4) 1.09 (0.90–1.32) 1.09 (0.89–1.34)
aAdjusted for age.
bAdjusted for age, BMI, age at menarche, marital status, education, parity, menopausal status, and family history of breast cancer.
Values in bold indicate statistical significance.
doi:10.1371/journal.pone.0037275.t002
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of this study’s point of interest. Recall bias is another unavoidable
concern in a case-control study. However, misclassification due to
recall bias occurred equally in both groups of patients and
controls. This non-differential misclassification meets the condi-
tions to reduce test power and bias study estimators toward no
association [49]. In the present study, moreover, due to an
awareness of their disease status, patients might be more likely to
recall their fever histories than controls, resulting in a more
underestimated association. Therefore, the positive association
between febrile infections and breast cancer risk cannot be
completely explained by biased information. All of the participants
in the present study were Han Chinese. Therefore, the results were
not affected by population admixture or genetic heterogeneity. In
addition, the frequency of the IFN-c rs2069705 C allele among the
healthy controls was 0.73 in our study, which was similar to that
Table 3. Multivariate odds ratio of breast cancer associated with previous fever frequency stratified by clinicopathological
characteristics.
Characteristics Fever frequency IFN-c rs2069705
Frequency
(time/year) Casesn (%) Controlsn (%) OR (95%CI)
a Genotype Cases n (%)
Controls
n (%) OR (95%CI)
a
Menopause
Premenopausal ,1 330 (76.6) 268 (73.8) 1.00 (reference) CC 242 (52.7) 207 (52.5) 1.00 (reference)
$1 101 (23.4) 95 (26.2) 0.82 (0.58–1.15) CT/TT 217 (47.3) 187 (47.5) 0.96 (0.73–1.28)
Postmenopausal ,1 224 (75.4) 278 (69.8) 1.00 (reference) CC 156 (47.9) 219 (52.8) 1.00 (reference)
$1 73 (24.6) 120 (30.2) 0.71 (0.50–1.03) CT/TT 170 (52.1) 196 (47.2) 1.18 (0.86–1.61)
P
a for interaction (multiplicative/additive) 0.685/0.596 0.491/0.750
BMI
,24 ,1 341 (73.5) 349 (70.9) 1.00 (reference) CC 261 (52.2) 277 (53.0) 1.00 (reference)
$1 123 (26.5) 143 (29.1) 0.88 (0.65–1.18) CT/TT 239 (47.8) 246 (47.0) 0.97 (0.75–1.26)
$24 ,1 198 (81.1) 180 (72.6) 1.00 (reference) CC 123 (46.4) 135 (51.7) 1.00 (reference)
$1 46 (18.9) 68 (27.4) 0.53 (0.33–0.84) CT/TT 142 (53.6) 126 (48.3) 1.24 (0.86–1.78)
P
a for interaction (multiplicative/additive) 0.099/0.057 0.293/0.148
Clinical stage
Localized ,1 306 (75.2) 560 (72.1) 1.00 (reference) CC 211 (47.7) 442 (52.6) 1.00 (reference)
$1 101 (24.8) 217 (27.9) 0.83 (0.62–1.11) CT/TT 231 (52.3) 398 (47.4) 1.18 (0.93–1.49)
Regional/distant ,1 207 (76.7) 560 (72.1) 1.00 (reference) CC 158 (52.7) 442 (52.6) 1.00 (reference)
$1 63 (23.3) 217 (27.9) 0.75 (0.53–1.05) CT/TT 142 (47.3) 398 (47.4) 0.99 (0.75–1.32)
P
a for heterogeneity test 0.469 0.184
ER
Positive ,1 367 (75.1) 560 (72.1) 1.00 (reference) CC 273 (51.0) 442 (52.6) 1.00 (reference)
$1 122 (24.9) 217 (27.9) 0.83 (0.63–1.08) CT/TT 262 (49.0) 398 (47.4) 1.05 (0.84–1.32)
Negative ,1 150 (79.4) 560 (72.1) 1.00 (reference) CC 107 (50.2) 442 (52.6) 1.00 (reference)
$1 39 (20.6) 217 (27.9) 0.67 (0.45–1.00) CT/TT 106 (49.8) 398 (47.4) 1.08 (0.79–1.48)
P
a for heterogeneity test 0.235 0.911
PR
Positive ,1 317 (74.8) 560 (72.1) 1.00 (reference) CC 247 (52.2) 442 (52.6) 1.00 (reference)
$1 107 (25.2) 217 (27.9) 0.86 (0.65–1.14) CT/TT 226 (47.8) 398 (47.4) 1.01 (0.80–1.28)
Negative ,1 199 (78.7) 560 (72.1) 1.00 (reference) CC 133 (48.5) 442 (52.6) 1.00 (reference)
$1 54 (21.3) 217 (27.9) 0.66 (0.46–0.94) CT/TT 141 (51.5) 398 (47.4) 1.15 (0.86–1.53)
P
a for heterogeneity test 0.123 0.459
HER2
Positive/equivocal ,1 153 (75.7) 560 (72.1) 1.00 (reference) CC 115 (50.2) 442 (52.6) 1.00 (reference)
$1 49 (24.3) 217 (27.9) 0.82 (0.56–1.19) CT/TT 114 (49.8) 398 (47.4) 1.09 (0.80–1.48)
Negative ,1 354 (76.5) 560 (72.1) 1.00 (reference) CC 258 (51.3) 442 (52.6) 1.00 (reference)
$1 109 (23.5) 217 (27.9) 0.78 (0.59–1.03) CT/TT 245 (48.7) 398 (47.4) 1.03 (0.82–1.30)
P
a for heterogeneity test 0.969 0.682
aAdjusted for age, BMI, age at menarche, marital status, education, parity, menopausal status, and family history of breast cancer (excluded the stratified factor in each
stratum).
Values in bold indicate statistical significance.
doi:10.1371/journal.pone.0037275.t003
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population and 0.81 in another Korean population [28,50].
In summary, our findings indicate a possible link between fever
history and a decreased risk of breast cancer for the first time,
providing novel information for prevention of breast cancer, or
even other cancers, in line with previous reports on the association
between infections and melanoma risk conducted by Kolmel KF et
al [6,38]. Moreover, we find that the association of fever frequency
with the risk of breast cancer was significantly modified by a
genetic polymorphism of IFN-c rs2069705 and that the association
of the polymorphism with the risk of breast cancer was
significantly modified by previous fever frequency, which may
provide new insight into hyperthermic treatment and interferon
therapy. The possible antitumor effects of fever, as shown in the
present study, also have important implications for the prudent
clinical and public use of antibiotics and antipyretics.
Materials and Methods
Study population
Female patients, newly histologically diagnosed with breast
cancer between October 2008 and June 2010 in the First and
Second Affiliated Hospitals and the Cancer Center of Sun Yat-sen
University in Guangzhou, China, were consecutively recruited to
this study. The study methods are described elsewhere [51]. A
total of 839 eligible breast cancer cases during the study period
completed in-person interviews with response rates of 75% to 85%
depending on the hospitals. Age (within 5 years) frequency-
matched female controls were identified from the primary care
databases of the same hospitals as breast cancer cases during the
same period. Women who self-reported a history of cancer were
excluded. Of the eligible controls, 863 (78.2%) completed in-
person interviews. All subjects must have resided in the
Guangzhou area for at least 5 years. Written informed consent
was obtained for the interviews and the specimen collections from
each subject. The Ethical Committee of the School of Public
Health at Sun Yat-sen University approved the study.
Data collection and laboratory protocol
Cases and controls were interviewed face-to-face by trained
interviewers using the same questionnaire. The following infor-
mation was obtained from the interviews: menstrual and
reproductive history, personal history of diseases including febrile
acute infections, family history of cancer, height and weight, and
demographic factors. In the instance of infections, subjects were
asked to recall the average number of times per year during the
last 10 years that they had experienced a fever or body
temperature $38uC as the result of acute febrile infections
including influenza, common cold, infectious enteritis, bronchitis,
pneumonia, and herpes simplex (,1, 1,2, 3,4, or $5 times).
Information about these infections was successfully collected from
731 cases (87.1% of those eligible) and 777 controls (90.0% of
those eligible). The interviewers did not know the hypotheses of
this study.
Blood samples were collected immediately after admission to the
hospital for patients or after the interview for controls and were
stored at 280uC. The clinical characteristics of the breast cancer
patients were collected from medical records. The statuses of
oestrogen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2) for the breast cancer
were determined by pathologists using immunohistochemistry
tests. The definitions of statuses of ER, PR and HER2 statuses
were described in detail in our previous study [52].
Genomic DNA was extracted from the buffy coats of the
participants using the TIANamp Genomic DNA Kit (TianGen
Biotech Co., Ltd., Beijing, China) and genotyped using a matrix-
assisted laser desorption/ionization time-of-flight (MALDI-TOF)
mass spectrometry platform (Sequenom, San Diego, California,
USA), according to the manufacturer’s instructions. The details of
the primers are described elsewhere [51]. Duplicate samples (5%
of the total) were included for the evaluation of genotyping quality
and the concordance rate was 100%. Genotyping was successfully
performed among 807 (96.2%) cases and 840 (97.3%) controls for
IFN-c rs2069705. No deviation from the Hardy-Weinberg
equilibrium was observed (P=0.350 in control group).
Table 4. Multivariate odds ratio of breast cancer associated with previous fever frequency by genotype of IFN-c rs2069705.
Variables Variables Cases, n (%) Controls, n (%) OR (95%CI)
a OR (95%CI)
b
Genotype IFN-c rs2069705 Fever frequency (/year)
CC ,1 time 255 (72.9) 297 (73.7) 1.00 (reference) 1.00 (reference)
$1 times 95 (27.1) 106 (26.3) 1.05 (0.76–1.45) 1.09 (0.77–1.55)
CT/TT ,1 time 279 (79.5) 248 (69.9) 1.00 (reference) 1.00 (reference)
$1 times 72 (20.5) 107 (30.1) 0.60 (0.42–0.84) 0.54 (0.37–0.77)
Fever frequency (/year) Genotype IFN-c
rs2069705
,1 time CC 255 (46.2) 297 (53.8) 1.00 (reference) 1.00 (reference)
CT/TT 279 (52.9) 248 (47.1) 1.31 (1.03–1.67) 1.32 (1.03–1.70)
$1 times CC 95 (47.3) 106 (52.7) 1.00 (reference) 1.00 (reference)
CT/TT 72 (40.2) 107 (59.8) 0.75 (0.50–1.12) 0.63 (0.40–0.99)
P
b for interaction (multiplicative/additive) 0.020/0.055 0.005/0.058
aAdjusted for age.
bAdjusted for age, BMI, age at menarche, marital status, education, parity, menopausal status, and family history of breast cancer.
Values in bold indicate statistical significance.
doi:10.1371/journal.pone.0037275.t004
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The differences in demographic characteristics and common
risk factors for breast cancer between the cases and controls were
tested using the x
2 test (for categorical variables) or Student’s t-test
(for continuous variables). Differences in fever frequency between
cases and controls were tested using the Mann-Whitney U test.
The Hardy–Weinberg equilibrium for IFN-c rs2069705 was
evaluated using a goodness-of-fit x
2 test to compare the observed
genotype frequency with the expected one among the controls.
Multivariate logistic regression models were used to assess the
effects of fever history and genotype on breast cancer risk,
controlling for age and for the potential risk factors of breast
cancer (age, BMI, age at menarche, marital status, education,
parity, menopausal status, and family history of breast cancer),
which were defined categorically with the exception of age
(Table 1). Models were fit using fever frequencies as categorical
variable. For evaluating the dose-response association between
fever frequency and the risk of breast cancer, tests for trends were
performed by entering the categorical variables as continuous
variables in the model. Stratified analyses for the associations
between fever frequency, genotype, and the risk of breast cancer
were performed by menopausal status, BMI, and clinical
characteristics. The heterogeneity of the odds ratios between the
different clinical characteristics levels was assessed using a
multivariable logistic regression model restricted to cases (case-
only analysis) with the clinical characteristics as the outcome
variables and adjusting for potential breast cancer risk factors. We
assumed a dominant inheritance for IFN-c rs2069705 and the
mutant homozygotes and heterozygotes were combined because
the effects’ directions of the CT and TT genotypes were the same
(OR.1).
The interaction between fever frequency and genotype on
breast cancer risk was evaluated by multiplicative and additive
models. We tested for multiplicative interaction by including the
product term in multivariate logistic regression. Additive interac-
tion was assessed using a method proposed by Rothman [53,54].
All statistical tests were two-tailed with P,0.05 considered to be
significant. Statistical analyses were performed using SAS 9.2 (SAS
Institute Inc., Cary, NC, USA).
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